H

HK Inno.N Corp
KOSDAQ:195940

Watchlist Manager
HK Inno.N Corp
KOSDAQ:195940
Watchlist
Price: 51 500 KRW -0.19% Market Closed
Market Cap: 1.5T KRW

HK Inno.N Corp
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

HK Inno.N Corp
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
H
HK Inno.N Corp
KOSDAQ:195940
Cash & Cash Equivalents
â‚©45.4B
CAGR 3-Years
-20%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Cash & Cash Equivalents
â‚©332.3B
CAGR 3-Years
20%
CAGR 5-Years
-10%
CAGR 10-Years
3%
SK Biopharmaceuticals Co Ltd
KRX:326030
Cash & Cash Equivalents
â‚©221B
CAGR 3-Years
25%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Cash & Cash Equivalents
â‚©78.5B
CAGR 3-Years
-20%
CAGR 5-Years
-7%
CAGR 10-Years
-3%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Cash & Cash Equivalents
â‚©81.5B
CAGR 3-Years
22%
CAGR 5-Years
12%
CAGR 10-Years
10%
C
Caregen Co Ltd
KOSDAQ:214370
Cash & Cash Equivalents
â‚©21.4B
CAGR 3-Years
3 705%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
No Stocks Found

HK Inno.N Corp
Glance View

Market Cap
1.5T KRW
Industry
Pharmaceuticals

HK inno.N Corp. engages in the provision of healthcare services. The company is headquartered in Chungju, Chungcheongbuk-Do. The company went IPO on 2021-08-09. The firm operates its business through three segments. The Prescription Drug segment is engaged in the manufacture and sale of hormone drugs, anticancer drugs, high blood pressure drugs, gastroesophageal reflux disease drugs, blood nutrient supplies, the circulatory system and others. The Health Beauty and Beverage (HB&B) segment is engaged in the manufacture and sale of products such as hangover relieving products, as well as health drinks and food products. The Other segment is engaged in the trademark royalties business and other services. The firm sells its products within domestic market and to overseas markets.

Intrinsic Value
67 869.95 KRW
Undervaluation 24%
Intrinsic Value
Price
H

See Also

What is HK Inno.N Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
45.4B KRW

Based on the financial report for Dec 31, 2024, HK Inno.N Corp's Cash & Cash Equivalents amounts to 45.4B KRW.

What is HK Inno.N Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-6%

Over the last year, the Cash & Cash Equivalents growth was -58%. The average annual Cash & Cash Equivalents growth rates for HK Inno.N Corp have been -20% over the past three years , -6% over the past five years .

Back to Top